D. E. Shaw and affiliated reporting persons filed Amendment No. 6 to their beneficial ownership statement on October 29, 2026, disclosing that as of October 27, 2026, their aggregate stake in Gossamer Bio, Inc. (NASDAQ:GOSS) fell below 5 percent of outstanding common shares.

Key Highlights

  • Ownership threshold crossed: On October 27, 2026, Valence, DESCO LLC, DESCO LP, and David E. Shaw ceased to be beneficial owners of more than 5 percent of Gossamer Bio common shares, according to the filing.
  • Valence position: D. E. Shaw Valence Portfolios, L.L.C. reported beneficial ownership of 243,041 common shares, representing approximately 4.0% of outstanding shares.
  • Aggregate D. E. Shaw group position: D. E. Shaw & Co., L.L.C., D. E. Shaw & Co., L.P., and David E. Shaw each reported shared beneficial ownership of 255,431 common shares, representing approximately 4.2% of the class.
  • Shares outstanding basis: The filing states there were 6,116,391 common shares issued and outstanding as of September 14, 2026, per the issuer's definitive proxy statement filed September 16, 2026.
  • Cogence position: D. E. Shaw Cogence Portfolios beneficially owned 12,390 common shares, representing approximately 0.2% of outstanding common shares.
  • Disclaimer of beneficial ownership: DESCO LP, DESCO LLC, DESCO Inc., DESCO II, Inc., and David E. Shaw each disclaimed beneficial ownership of the common shares attributed to them.

D. E. Shaw Reduces Stake in Gossamer Bio Below Reporting Threshold

According to the filing, this Amendment No. 6 was submitted to amend and supplement the original Schedule 13D first filed on June 11, 2026, and subsequently updated through five prior amendments. The triggering event was October 27, 2026, the date on which Valence, DESCO LLC, DESCO LP, and David E. Shaw, in their respective capacities, fell below beneficial ownership of more than 5 percent of Gossamer Bio's common stock, par value $0.0001 per share (CUSIP: 38341P201).

The filing identifies two portfolio entities holding the shares: D. E. Shaw Valence Portfolios, L.L.C., which holds 243,041 common shares (approximately 4.0%), and D. E. Shaw Cogence Portfolios, which holds 12,390 common shares (approximately 0.2%). The filing states that D. E. Shaw & Co., L.P. serves as investment adviser to both Valence and Cogence, and that DESCO LLC serves as their manager, leading each to be attributed shared voting and dispositive power over the combined 255,431 shares. Gossamer Bio is a clinical-stage biopharmaceutical company headquartered at 3115 Merryfield Row, Suite 120, San Diego, California 92121, and its common stock is listed on NASDAQ.

David E. Shaw's attributed ownership arises indirectly through his role as President and sole shareholder of both DESCO Inc. (general partner of DESCO LP) and DESCO II, Inc. (managing member of DESCO LLC), as described in the filing. The filing notes that no reporting person holds common shares directly, and all parties disclaim beneficial ownership. Transactions in the issuer's securities since Amendment No. 5 are detailed in Schedule I filed as Exhibit 99.1.

What Was Disclosed

The D. E. Shaw group filed Amendment No. 6 to report that their combined beneficial ownership of Gossamer Bio common shares dropped below 5 percent as of October 27, 2026, with the aggregate attributed position standing at 255,431 shares, or approximately 4.2% of the class.